TD Waterhouse Canada Inc. Buys 29,365 Shares of Johnson & Johnson $JNJ

Key Points

• TD Waterhouse Canada increased its Johnson & Johnson stake by 3.0%, acquiring 29,365 shares to hold 1,005,440 shares valued at approximately $255.5 million. Institutional investors own 69.55% of J&J stock.
• J&J exceeded quarterly expectations with adjusted EPS of $2.90 and revenue of $25.31 billion, while revenue rose 6.6% year over year. The company reaffirmed fiscal 2026 EPS guidance of $11.60–$11.75.
• Shares were trading near their 12-month high at $265.91, and the company maintains a quarterly dividend of $1.34, equivalent to a 2.0% yield. Analysts collectively rate the stock “Moderate Buy,” with an average price target of $274.13, though valuation and slowing rally momentum remain concerns.

TD Waterhouse Canada Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,005,440 shares of the company's stock after acquiring an additional 29,365 shares during the quarter. TD Waterhouse Canada Inc.'s holdings in Johnson & Johnson were worth $255,484,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in JNJ. Silver Coast Investments LLC boosted its holdings in shares of Johnson & Johnson by 3.8% during the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock worth $271,000 after buying an additional 39 shares during the period. Townsend Asset Management Corp NC ADV raised its holdings in Johnson & Johnson by 0.6% in the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock worth $1,630,000 after acquiring an additional 39 shares during the period. Triumph Capital Management lifted its position in Johnson & Johnson by 1.6% during the 2nd quarter. Triumph Capital Management now owns 2,531 shares of the company's stock worth $643,000 after acquiring an additional 39 shares during the last quarter. Denali Advisors LLC lifted its position in Johnson & Johnson by 1.2% during the 2nd quarter. Denali Advisors LLC now owns 3,305 shares of the company's stock worth $839,000 after acquiring an additional 40 shares during the last quarter. Finally, Sierra Capital LLC boosted its holdings in Johnson & Johnson by 0.5% during the fourth quarter. Sierra Capital LLC now owns 8,144 shares of the company's stock valued at $1,685,000 after acquiring an additional 41 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 0.2%

JNJ stock opened at $265.91 on Friday. Johnson & Johnson has a twelve month low of $173.33 and a twelve month high of $281.07. The company has a market cap of $640.82 billion, a PE ratio of 30.81, a price-to-earnings-growth ratio of 2.54 and a beta of 0.24. The business's 50-day simple moving average is $263.03 and its 200 day simple moving average is $245.93. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm had revenue of $25.31 billion during the quarter, compared to analysts' expectations of $25.06 billion. During the same quarter in the prior year, the firm posted $2.77 EPS. The company's revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, research analysts anticipate that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is presently 62.11%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received CE Marking in Europe for ACUVUE OASYS MAX 2-Week reusable contact lenses, expanding its Vision Care product portfolio. The approval could support future sales, though its immediate financial impact is likely limited. Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
• Positive Sentiment: China approved Icotyde, J&J’s once-daily oral treatment for moderate-to-severe plaque psoriasis. The drug gives the company access to a large patient population and may attract patients who prefer an oral therapy to injectable alternatives, creating a potential growth catalyst. Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?
• Positive Sentiment: Investor-focused coverage continues to highlight J&J as a Dividend Aristocrat that has maintained and increased its payout through past crises, supporting its appeal as a defensive income stock. The company also recently exceeded quarterly earnings and revenue expectations. 3 Top Dividend Aristocrats To Own Near All-Time Highs
• Neutral Sentiment: J&J is trading near its 12-month high after a strong advance, indicating sustained market confidence but also leaving less room for upside without additional earnings growth.
• Negative Sentiment: Analysts are questioning whether the rally is losing momentum. With shares valued at roughly 31 times earnings, profit-taking or valuation concerns could weigh on the stock despite the company’s defensive qualities and new growth opportunities. JNJ Stock: Is the Rally Running Out of Steam?

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Morgan Stanley boosted their price objective on Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a research report on Thursday, July 16th. The Goldman Sachs Group reaffirmed a "buy" rating and issued a $282.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. Freedom Capital upgraded Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 16th. Scotiabank reissued an "outperform" rating and issued a $305.00 price objective on shares of Johnson & Johnson in a research report on Thursday, July 16th. Finally, Guggenheim raised their price objective on shares of Johnson & Johnson from $270.00 to $287.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $274.13.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the business's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 87,569 shares of company stock valued at $23,064,544 in the last ninety days. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.